Dietary Butyrate Enhances Anti-PD-1 Efficacy in NSCLC via Gut Microbiome Modulation
Dietary supplementation with butyrate enhances anti-tumor activity and improves the efficacy of α PD-1 therapy in mice, linked to immune cell modulation.
Asset / Drug
Drug and asset intelligence for Akkermansia with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.